Market Cap | 814.85M | P/E | - | EPS this Y | 4.00% | Ern Qtrly Grth | - |
Income | -95.99M | Forward P/E | -6.69 | EPS next Y | -7.90% | 50D Avg Chg | 33.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 56.00% |
Dividend | N/A | Price/Book | 5.17 | EPS next 5Y | - | 52W High Chg | -21.00% |
Recommedations | 1.80 | Quick Ratio | 7.21 | Shares Outstanding | 54.45M | 52W Low Chg | 254.00% |
Insider Own | 7.95% | ROA | -41.54% | Shares Float | 39.88M | Beta | 1.05 |
Inst Own | 87.32% | ROE | -107.50% | Shares Shorted/Prior | 6.31M/6.24M | Price | 18.41 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 701,819 | Target Price | 48.88 |
Oper. Margin | - | Earnings Date | May 9 | Volume | 377,642 | Change | -3.51% |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Guggenheim | Buy | Apr 5, 24 |
Guggenheim | Buy | Mar 27, 24 |
Wedbush | Neutral | Mar 21, 24 |
Wedbush | Neutral | Jan 26, 24 |
Raymond James | Strong Buy | Jan 26, 24 |
Oppenheimer | Outperform | Jan 25, 24 |
Cantor Fitzgerald | Overweight | Jan 8, 24 |
HC Wainwright & Co. | Buy | Dec 27, 23 |
Raymond James | Outperform | Dec 18, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Katabi Maha | Director Director | Jan 30 | Buy | 31.00 | 161,290 | 4,999,990 | 3,628,446 | 02/01/24 |
COMMODORE CAPITAL LP | 10% Owner 10% Owner | Jan 10 | Sell | 18.00 | 1,050,000 | 18,900,000 | 4,400,000 | 01/12/24 |
Fordyce Marshall | President and CEO President and CEO | Dec 29 | Option | 2.61 | 13,516 | 35,277 | 256,877 | 01/03/24 |
Lin Celia | Chief Medical Office.. Chief Medical Officer | Aug 21 | Sell | 16.6547 | 1,490 | 24,816 | 11,010 | 08/23/23 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Aug 21 | Sell | 16.6558 | 1,490 | 24,817 | 26,962 | 08/23/23 |
Fordyce Marshall | President and CEO President and CEO | Aug 21 | Sell | 16.6562 | 5,210 | 86,779 | 243,361 | 08/23/23 |
SEIDENBERG BETH C | Director Director | Feb 13 | Buy | 7.1972 | 10,072 | 72,490 | 1,664,702 | 02/15/23 |
SEIDENBERG BETH C | Director Director | Feb 09 | Buy | 7.25 | 400 | 2,900 | 1,654,630 | 02/13/23 |
Longitude Capital Partners IV,... | 10% Owner 10% Owner | Feb 06 | Buy | 7.00 | 1,714,285 | 11,999,995 | 1,714,285 | 02/08/23 |
ENRIGHT PATRICK G | Director Director | Feb 06 | Buy | 7.00 | 1,714,285 | 11,999,995 | 1,714,285 | 02/08/23 |
Sofinnova Venture Partners X,... | 10% Owner 10% Owner | Feb 06 | Buy | 7.00 | 285,714 | 1,999,998 | 3,467,156 | 02/08/23 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Nov 09 | Sell | 16.54 | 494 | 8,171 | 27,315 | 11/10/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Oct 18 | Option | 7.82 | 8,590 | 67,174 | 27,811 | 10/20/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Oct 18 | Sell | 19.63 | 8,590 | 168,622 | 27,809 | 10/20/22 |
Fordyce Marshall | President and CEO President and CEO | Sep 07 | Option | 2.9 | 21,891 | 63,484 | 196,256 | 09/09/22 |
Fordyce Marshall | President and CEO President and CEO | Sep 07 | Sell | 20.28 | 21,891 | 443,949 | 181,150 | 09/09/22 |
Carlyle Group Inc. | 10% Owner 10% Owner | Aug 17 | Option | 11 | 9,925 | 109,175 | 2,970,156 | 08/19/22 |
Carlyle Group Inc. | 10% Owner 10% Owner | Aug 17 | Sell | 20.46 | 9,925 | 203,066 | 2,960,231 | 08/19/22 |
Fordyce Marshall | President and CEO President and CEO | Aug 12 | Option | 2.9 | 20,528 | 59,531 | 157,928 | 08/15/22 |
Fordyce Marshall | President and CEO President and CEO | Aug 12 | Sell | 20.16 | 20,528 | 413,844 | 137,400 | 08/15/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Jul 19 | Option | 4.63 | 11,444 | 52,986 | 18,281 | 07/20/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Jul 19 | Sell | 16.28 | 11,444 | 186,308 | 18,273 | 07/20/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Jun 22 | Option | 6.37 | 1,239 | 7,892 | 25,233 | 06/23/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Jun 22 | Sell | 15.02 | 1,545 | 23,206 | 23,688 | 06/23/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Jun 17 | Option | 4.63 | 4,687 | 21,701 | 28,535 | 06/21/22 |
Curley Joanne | Chief Development Of.. Chief Development Officer | Jun 17 | Sell | 15.05 | 5,887 | 88,599 | 23,994 | 06/21/22 |
Longitude Capital Partners IV,... | 10% Owner 10% Owner | Feb 10 | Buy | 15.00 | 333,333 | 4,999,995 | 3,429,927 | 04/05/22 |
ENRIGHT PATRICK G | Director Director | Feb 10 | Buy | 15.00 | 333,333 | 4,999,995 | 3,429,927 | 04/05/22 |
Sofinnova Venture Partners X,... | 10% Owner 10% Owner | Feb 10 | Buy | 15 | 266,666 | 3,999,990 | 3,181,442 | 02/14/22 |